Dry Eye Disease

Timing is everything.

Summers mean slowing down. At least, they should. Even if it’s just a little bit.

A phase 3 pivotal study of PL9643, a melanocortin agonist under investigation as a treatment for dry eye disease, demonstrated positive interim results, according to a press release from Palatin Technologies.

Novaliq submitted a new drug application to the FDA for CyclASol, a cyclosporine ophthalmic solution for the treatment of dry eye disease signs and symptoms, according to a company press release.

Reproxalap 0.25% ophthalmic solution achieved primary and secondary endpoints in a trial investigating treatment of dry eye disease, Aldeyra Therapeutics announced in a press release.

The first subject has been dosed in the phase 3 registrational COMET-3 study investigating AR-15512 for the treatment of dry eye disease, according to a press release from Aerie Pharmaceuticals.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, discuss the latest ophthalmic industry news and interview Allison W. Shuren, JD, MSN.

A range of factors, or triggers, that affect the ocular surface can cause dry eye flares of varying intensity.

Last month I shared my thoughts on where the winds were blowing as we look toward the near future of dry eye disease treatment.

The first patient has been enrolled in a phase 2 clinical study evaluating YP-P10 for the treatment of dry eye disease, according to a press release from Yuyu Pharma.